Although short-term treatment of murine orthotopic tumors with olaparib did not provide any significant benefit, long-term treatment significantly suppressed tumor development in Brca1- deficient but not in Brca1-wild type tumors, similar to the progression free survival benefit observed in patients [15], [16], [47]. This evidence concerns the gene BRCA1 and neoplasm.